WallStreetZenWallStreetZen

NASDAQ: INDP
Indaptus Therapeutics Inc Stock Ownership - Who owns Indaptus Therapeutics?

Insider buying vs selling

Have Indaptus Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Jeffrey A. MecklerCEO and Director2024-08-0884,932$1.83
$155.00kBuy

1 of 1

INDP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INDP insiders and whales buy or sell their stock.

INDP Shareholders

What type of owners hold Indaptus Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Dexcel Pharma Technologies Ltd41.53%4,234,897$6.06MInsider
Michael James Newman13.42%1,368,356$1.96MInsider
Glen R. Anderson12.79%1,304,318$1.87MInsider
Vanguard Group Inc2.51%256,265$366.46kInstitution
Jeffrey A. Meckler1.57%160,306$229.24kInsider
John W. Kozarich1.49%151,761$217.02kInsider
Investment House LLC1.00%102,437$146.48kInstitution
Geode Capital Management LLC0.58%59,309$84.81kInstitution
Anthony J. Maddaluna0.53%53,570$76.61kInsider
Strategy Asset Managers LLC0.44%45,336$64.83kInstitution

1 of 3

INDP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INDP5.88%71.67%Net BuyingNet Buying
NRSN10.87%0.00%
IMRN0.01%0.00%
XTLB0.05%20.78%
INAB16.55%48.15%Net Buying

Indaptus Therapeutics Stock Ownership FAQ

Who owns Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ: INDP) is owned by 5.88% institutional shareholders, 71.67% Indaptus Therapeutics insiders, and 22.45% retail investors. Dexcel Pharma Technologies Ltd is the largest individual Indaptus Therapeutics shareholder, owning 4.23M shares representing 41.53% of the company. Dexcel Pharma Technologies Ltd's Indaptus Therapeutics shares are currently valued at $6.06M.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.